Eagle Asset Management’s Coherus Oncology CHRS Stock Holding History

Eagle Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,129	Closed	-$49.1K	–	567
2023 Q3	$49.1K	Hold	13,129	–	–	﹤0.01%	534
2023 Q2	$56.1K	Buy	+13,129	New	+$77.5K	﹤0.01%	530
2022 Q2	–	Sell	-243,404	Closed	-$3.14M	–	569
2022 Q1	$3.14M	Sell	243,404 -121,931	-33%	-$1.55M	0.02%	428
2021 Q4	$6.12M	Sell	365,335 -67,289	-16%	-$1.18M	0.03%	382
2021 Q3	$6.95M	Sell	432,624 -63,917	-13%	-$937K	0.03%	367
2021 Q2	$6.87M	Buy	496,541 +114,033	+30%	+$1.61M	0.03%	386
2021 Q1	$5.57M	Sell	382,508 -14,212	-4%	-$241K	0.02%	400
2020 Q4	$6.89M	Sell	396,720 -7,711	-2%	-$137K	0.04%	341
2020 Q3	$7.61M	Buy	404,431 +6,631	+2%	+$123K	0.04%	317
2020 Q2	$6.89M	Buy	+397,800	New	+$6.73M	0.04%	332

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Asset Management's CHRS Position: Q4 2023 in Review

Eagle Asset Management sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 13,129 shares — an estimated $49.1K sold.

Eagle Asset Management first reported a position in CHRS in Q2 2020 and held it in 10 quarters. The position peaked at $7.61M in Q3 2020. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

Eagle Asset Management reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
Eagle Asset Management sold 13,129 Coherus Oncology shares in Q4 2023, an estimated $49.1K.
Eagle Asset Management first reported a position in Coherus Oncology in Q2 2020 and held it in 10 quarters.
Eagle Asset Management's Coherus Oncology position peaked at $7.61M in Q3 2020.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Eagle Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.